Veritas In Silico Inc. 130A

TSE · Japan · Health Technology

¥434.00+2.00 (+0.46%)

Market closed· Oct 2, 2026, 6:30 AM UTC· JPY · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Veritas In Silico Inc. 130A

TSE · Japan · Health Technology

¥434.00+2.00 (+0.46%)

Market closed· Oct 2, 2026, 6:30 AM UTC· JPY · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-5.03% · 6MFull-screen chart

Open ¥433.00High ¥441.00Low ¥429.00Close ¥434.00Volume 7.60K

Oct 2, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: ¥432.00
Day range: ¥429.00 – ¥441.00
52-week range: ¥390.00 – ¥793.00
Volume: 7.60K
Market cap: ¥2.80B
Next earnings date: 2026-11-13
Avg. volume (1Y): 74.10K

Performance

1 week

+0.93%

1 month

+0.23%

3 months

+0.23%

6 months

-5.24%

Year to date

-8.63%

1 year

-36.83%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Biotechnology
Country: Japan
Exchange: TSE
Shares outstanding: 6.49M
Employees: 19
ISIN: JP3155340007
Beta: 0.17

Technical view

Mixed

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceApr 21, 2026

Takeda Ends Veritas In Silico Pact As mRNA Focus And Valuation Watched

Takeda Pharmaceutical (TSE:4502) has ended its collaborative research agreement with Veritas In Silico Inc. on mRNA targeted small molecule drugs. The decision concludes a research partnership that focused on discovering therapies by targeting mRNA with small molecules. The company has indicated that the effect on near term business performance is limited, but the move may matter for its longer term research direction in mRNA related projects. For investors watching Takeda Pharmaceutical at...

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.